MiMedx Group, Inc. (MDXG)

Market Cap	1.00B
Revenue (ttm)	352.38M
Net Income (ttm)	40.18M
Shares Out	147.70M
EPS (ttm)	0.27
PE Ratio	24.67
Forward PE	26.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	349,380
Open	6.62
Previous Close	6.66
Day's Range	6.61 - 6.77
52-Week Range	5.47 - 10.14
Beta	1.76
Analysts	Strong Buy
Price Target	12.50 (+83.96%)
Earnings Date	Jul 30, 2025

About MDXG

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 837
• Stock Exchange: NASDAQ
• Ticker Symbol: MDXG
• Website: https://www.mimedx.com

Financial Performance

In 2024, MiMedx Group's revenue was $348.88 million, an increase of 8.52% compared to the previous year's $321.48 million. Earnings were $42.42 million, a decrease of -8.94%.

Analyst Summary

According to 2 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 83.96% from the latest price.

Price Target

$12.5

(83.96% upside)

Analyst Consensus: Strong Buy